10.02.24
The KD Pharma Group, a CDMO in pharmaceutical and nutritional lipids, has completed the acquisition of dsm-firmenich’s marine lipids business, after it was first announced in July.
The acquisition includes dsm-firmenich’s omega-3 fish oil business for the food, beverage, supplement, and pharmaceutical markets, as well as the MEG-3 brand and production facilities in Piura, Peru and Mulgrave, Canada. In return, dsm-firmenich has received a minority stake in KD Pharma Group.
"This is a historic day for our company. We are excited about the new opportunities that lie ahead of us, which will allow us to better advance our mission of creating innovative health solutions that help people live better lives,” said KD Pharma Group. “We now have a leadership position throughout the value chain from refined oils to pharmaceutical APIs to softgel capsule manufacturing. We are committed to ensuring that our customers from both businesses have a seamless experience as we integrate the acquisition and promise they will receive the highest levels of service and market-leading quality.”
The expanded KD Pharma group now has 710 employees and seven manufacturing facilities in the U.K., Norway, Germany, Canada, Peru, and the U.S.
The acquisition includes dsm-firmenich’s omega-3 fish oil business for the food, beverage, supplement, and pharmaceutical markets, as well as the MEG-3 brand and production facilities in Piura, Peru and Mulgrave, Canada. In return, dsm-firmenich has received a minority stake in KD Pharma Group.
"This is a historic day for our company. We are excited about the new opportunities that lie ahead of us, which will allow us to better advance our mission of creating innovative health solutions that help people live better lives,” said KD Pharma Group. “We now have a leadership position throughout the value chain from refined oils to pharmaceutical APIs to softgel capsule manufacturing. We are committed to ensuring that our customers from both businesses have a seamless experience as we integrate the acquisition and promise they will receive the highest levels of service and market-leading quality.”
The expanded KD Pharma group now has 710 employees and seven manufacturing facilities in the U.K., Norway, Germany, Canada, Peru, and the U.S.
